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background: Whether primary prevention implantable cardioverter-defibrillators (ICDs) are efficacious among older patients is uncertain.
methods: We merged patient-level data from 5 primary prevention trials randomizing patients to an ICD or usual care: the Multicenter Automatic 
Defibrillator Implantation Trial I, the Multicenter UnSustained Tachyardia Trial, the Multicenter Automatic Defibrillator Implantation Trial II, the 
Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation trial, and the Sudden Cardiac Death in Heart Failure Trial.
results: Median age at enrollment was 62 (interquartile range 53-70) years. ICD recipients were less likely to die than non-recipients in all 
age groups: 43/527 (8.2%) vs 84/483(17.4%) among patients <55 years; 97/528 (18.4%) vs 139/527 (26.4%) among patients 55-64 years; 
127/555(22.9%) vs 174/520 (33.5%) among patients 65-74 years; and 56/226(24.8%) vs 66/164 (40.2%) among patients > 75 years. The 
sample size was limited among patients > 75 years. In adjusted Bayesian Weibull modeling, point estimates for ICD efficacy were consistent with 
a survival benefit across the spectrum of age; however, the benefit appeared to decrease with increasing age (Figure). There was evidence of an 
interaction between age and ICD treatment on survival (posterior probability of no interaction < 0.01).
conclusions: In this analysis, the survival benefit of the ICD is attenuated with increasing age. More data are needed, particularly among patients 
> 75 years.
